Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Expands Alcon’s retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease Alcon's established presence and